As cash-strapped California looks to trim its state budget, the state gets a powerful return on its investment in UCSF—which accounted for about 7 percent of the University’s total revenues in fiscal year 2009. The report reveals that UCSF has been the source of about 90 biotech start-ups, 95 percent of all University of California patents, more than $64 million in patent royalties and fees over the past decade, and more than $400 million annually in National Institutes of Health (NIH) grants.
The California Institute for Regenerative Medicine, approved by state voters in 2004, and now headquartered near the Mission Bay campus, has so far committed more than $100 million to UCSF’s program, including $34.9 million to support UCSF’s Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, now under construction and nearing completion at the Parnassus Heights campus.
UCSF is also home to the California Institute for Quantitative Biosciences (QB3), itself an innovative organization established by the state and run by UCSF, UC Berkeley, and UC Santa Cruz. At QB3’s Mission Bay headquarters, more than 170 researchers explore how biological systems work, use advanced computational tools, and discover groundbreaking applications for health, energy, and the environment. QB3 also provides mechanisms for scientists to interact with their counterparts in industry, often to help speed research and bring a new therapy or tool to market faster. So far, about 90 life sciences start-up companies have been spawned at or spun off from UCSF labs.
For more information, contact:
Associate Director, State and Local Government Relations